Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre observational registry of Northern Italy. METHODS: We extracted data of patients who started treatment with golimumab from October 2010, and who had at least one follow-up visit. Data were analysed until a maximum follow-up of 24 months. The two-year retention rate in the three diseases was assessed with Kaplan-Meier estimators. To compare crude survival between diagnoses and lines of treatment we used the log-rank test, while Cox proportional hazard models were used to adjust for confounders. RESULTS: Overall, 410 subjects were included: 180 patients with RA, 110 with PsA and 120 with AS. The two-year retention rate of patients with RA was 47.3%, 48% for PsA, and 62.8% for AS. Crude survival on treatment of patients with AS was significantly higher than that of RA patients (p=0.032), while no significant difference was found between AS and PsA and between RA and PsA. In patients with RA, subjects treated with concomitant sDMARDs showed a lower discontinuation rate than those receiving golimumab alone. The comparison between first and second line of treatment groups did not show any significant difference in mean survival time in patients with RA, PsA and AS. CONCLUSIONS: This is the first report of real-life data on two-year survival on treatment with golimumab in RA, PsA and AS. Golimumab showed a similar retention rate when given as first or second line of treatment.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
Istituto Ortopedico Gaetano Pini pays non établi dans la noticeÉtablissement de santé
-
University of Pavia Department of Rheumatology pays non établi dans la noticeUniversité ou école supérieure
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
Luigi Sacco Hospital pays non établi dans la noticeÉtablissement de santé
-
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia pays non établi dans la noticeÉtablissement de santé
-
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino pays non établi dans la noticeÉtablissement de santé
-
A. O. Ordine Mauriziano di Torino pays non établi dans la noticeÉtablissement de santé
-
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo pays non établi dans la noticeÉtablissement de santé
-
Gaetano Pini Institute Department of Rheumatology pays non établi dans la noticeStructure de recherche
-
L. Sacco University Hospital Rheumatology Unit pays non établi dans la noticeUniversité ou école supérieure
-
Rheumatology and Immunology Unit pays non établi dans la noticeInstitution
-
Department of Rheumatology pays non établi dans la noticeInstitution
Istituto Ortopedico Gaetano Pini, Department of Rheumatology — University of Pavia et Istituti di Ricovero e Cura a Carattere Scientifico, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.